Globela Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Globela Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $3.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Globela Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $3.3M Trade | TransData Nexus

Globela Pharma Private Limited

Indian Pharmaceutical Exporter · Antifungals Specialist · $3.3M Total Trade · DGFT Verified

Globela Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.3M across 9 products in 5 therapeutic categories. Based on 139 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Fluconazole ($1.5M), Erythromycin ($750.0K), Febuxostat ($565.3K).

Globela Pharma Private Limited — Export Portfolio & Destination Treemap

Globela Pharma Private Limited pharmaceutical export portfolio — 9 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Globela Pharma Private Limited? — Company Overview & Market Position

Globela Pharma Private Limited, established on February 8, 2006, is a privately held pharmaceutical manufacturing company headquartered in Surat, Gujarat, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets. Globela Pharma is registered under the Corporate Identification Number (CIN) U24230GJ2006PTC047699.

The company's authorized capital stands at ₹68.5 crore, with a paid-up capital of ₹56.92 crore, reflecting a strong financial foundation. Globela Pharma operates with a dedicated workforce of approximately 201 to 500 employees, as indicated on their LinkedIn profile. Their official website, www.globelapharma.com, provides comprehensive information about their products, services, and global presence.

What Does Globela Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fluconazole$1.5M 2Erythromycin

Product Portfolio — Top 9 by Export Value

Globela Pharma Private Limited exports 9 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fluconazole	Antifungals	$1.5M	32	1.6%	14
2	Erythromycin	Antibiotics	$750.0K	15	0.9%	14
3	Febuxostat	Lipid & Metabolism	$565.3K	40	1.2%	9
4	Ritonavir	Antiviral & HIV Medications	$276.5K	13	0.1%	10
5	Letrozole	Advanced Oncology	$154.0K	9	0.5%	12
6	Anastrozole	Advanced Oncology	$54.4K	7	0.0%	12
7	Dasatinib	Advanced Oncology	$25.4K	8	0.2%	14
8	Thalidomide	Advanced Oncology	$23.0K	9	1.2%	9
9	Mercaptopurine	Advanced Oncology	$10.3K	6	1.8%	10

Globela Pharma Private Limited exports 9 pharmaceutical products across 5 therapeutic categories with a total export value of $3.3M. The top category is Antifungals (43.8% of portfolio), followed by Antibiotics (22.7%), indicating a concentrated portfolio with the top 5 products accounting for 96.6% of total export value.

Globela Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Globela Pharma's manufacturing facility is strategically located at Plot No. 357 - 358, Road No. 3 GIDC, Sachin, Surat, Gujarat, India. The plant is equipped with state-of-the-art infrastructure and adheres to stringent quality standards, including WHO-GMP and EU-GMP certifications. This facility specializes in the production of high-quality pharmaceutical products, with dedicated units for oncology (anti-cancer) formulations and cephalosporins, ensuring compliance with global regulatory requirements.

3Key Leadership

The leadership team at Globela Pharma Private Limited comprises experienced professionals committed to driving the company's growth and innovation. Bhanubhai Shambhubhai Vaghashia serves as the Managing Director, having been appointed on February 8, 2006. Urmilaben Bhanubhai Vaghasiya holds the position of Director, with an appointment date of October 25, 2010. Additionally, Priyank Vaghashia and Mayur Anand Sirdesai joined the board as Directors on September 23, 2021, and January 13, 2022, respectively. The company's leadership is further strengthened by Pietro Ermanno Stefanutti, who was appointed as a Director on January 13, 2022.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Globela Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Globela Pharma Private Limited has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from multiple overseas regulatory authorities, such as Myanmar, Sri Lanka, Vietnam, Cambodia, Nigeria, Kenya, and Tanzania, indicating a robust international footprint. While specific details regarding regulatory filings and market access in the U.S., EU, UK, Australia, and Japan are not publicly disclosed, the company's adherence to WHO-GMP and EU-GMP standards suggests a commitment to meeting international regulatory requirements.

2Emerging Markets

Globela Pharma has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's products are registered in over 50 countries, including regions such as Venezuela, Chile, Nigeria, Myanmar, Kenya, Philippines, Sri Lanka, Ghana, and Vietnam. This extensive reach is facilitated by the company's WHO-GMP and EU-GMP certifications, which enable access to these markets.

3Geographic Strategy

Globela Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Globela Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to WHO-GMP and EU-GMP standards indicates a commitment to quality manufacturing practices, which are essential for FDA approvals. However, without explicit information, it is challenging to assess the company's current status with the FDA.

2WHO & EU GMP

Globela Pharma holds WHO-GMP and EU-GMP certifications, demonstrating compliance with international manufacturing standards. These certifications are crucial for accessing global markets and ensuring product quality. The company's manufacturing facility is also ISO 9001:2015 certified, reflecting a commitment to quality management systems.

3CDSCO & Indian Regulatory

Globela Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is WHO-GMP and EU-GMP certified, indicating compliance with international standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to global standards suggests a strong regulatory standing within India.

Globela Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Globela Pharma operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. Top competitors include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. While Globela Pharma's export value of $3.3 million USD is modest compared to these industry giants, the company's focus on high-quality formulations and adherence to international standards positions it as a reliable supplier in niche markets. The company's specialization in oncology and cephalosporin products further differentiates it from competitors.

2Key Differentiators

Globela Pharma's key differentiators include its specialized facilities for oncology and cephalosporin formulations, adherence to WHO-GMP and EU-GMP standards, and a strong in-house R&D center approved by the Department of Scientific and Industrial Research (DSIR). These factors enable the company to offer high-quality, affordable pharmaceutical solutions tailored to the needs of diverse markets.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Globela Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Globela Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with an export value of $3.3 million USD from 139 shipments across nine products in five therapeutic categories. The company's adherence to WHO-GMP and EU-GMP standards, along with certifications from various overseas regulatory authorities, indicates reliability and commitment to quality. The company's specialization in oncology and cephalosporin products further underscores its expertise in these areas.

2Certifications to Verify

Importers should verify the following certifications when considering Globela Pharma as a supplier:

WHO-GMP Certification: Ensures compliance with World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

EU-GMP Certification: Confirms adherence to European Union's Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

Frequently Asked Questions — Globela Pharma Private Limited

How many pharmaceutical products does Globela Pharma Private Limited export from India?

Globela Pharma Private Limited exports 9 pharmaceutical products across 5 therapeutic categories. The top exports are Fluconazole ($1.5M), Erythromycin ($750.0K), Febuxostat ($565.3K), Ritonavir ($276.5K), Letrozole ($154.0K). Total export value is $3.3M.

What is Globela Pharma Private Limited's total pharmaceutical export value?

Globela Pharma Private Limited's total pharmaceutical export value is $3.3M, based on 139 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Globela Pharma Private Limited cover?

Globela Pharma Private Limited exports across 5 therapeutic categories. The largest are Antifungals (43.8%, 1 products), Antibiotics (22.7%, 1 products), Lipid & Metabolism (17.1%, 1 products).

Get Full Globela Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.